Anti-EGFR is an option in unresectable, relapsed, and/or metastatic cancer as a second-line treatment, associated or not associated with chemotherapy, after TIP/TPF failure (recommendation, LE: 4), showing a trend to a higher response rate compared with other chemotherapy regimens (Buonerba et al. 2016). The gene discussed is EGFR; the disease is metastatic malignant neoplasm.